Loading
A phase 2 trial of Bevacizumab, FOLFIRI in colorectal cancer, run by Oncolytics Biotech, now recruiting.
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer is a phase 2 interventional study registered as NCT07446322 by Oncolytics Biotech, with 60 participants planned, started 2026-04-30 and due to reach its primary completion in 2027-08-30. Interventions recorded: Bevacizumab, FOLFIRI, Pelareorep. Conditions listed: Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Anti-angiogenic therapy, Monoclonal antibodies, Colorectal cancer.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Colorectal cancer.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Colorectal cancer.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Monoclonal antibodies, Colorectal cancer.